143 related articles for article (PubMed ID: 37408508)
21. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
23. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.
Shah M; Jain AK; Brunelli SM; Coca SG; Devereaux PJ; James MT; Luo J; Molnar AO; Mrkobrada M; Pannu N; Parikh CR; Paterson M; Shariff S; Wald R; Walsh M; Whitlock R; Wijeysundera DN; Garg AX
BMC Nephrol; 2014 Apr; 15():53. PubMed ID: 24694072
[TBL] [Abstract][Full Text] [Related]
24. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease - Propensity Score Matching Analysis.
Kim HJ; Lee MH; Jo SH; Seo WW; Kim SE; Kim KJ; Choi JO; Ahn HS; Choi DJ; Ryu KH
Circ J; 2019 Dec; 84(1):83-90. PubMed ID: 31776309
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
Choksi TT; Zhang H; Chen T; Malhotra N
Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
27. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
28. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
[TBL] [Abstract][Full Text] [Related]
29. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
Takaori K; Iwatani H; Yamato M; Ito T
BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
[TBL] [Abstract][Full Text] [Related]
30. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
[TBL] [Abstract][Full Text] [Related]
31. Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.
Yoshioka K; Matsue Y; Yamaguchi T; Kitai T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Kuroda S; Matsumura A; Hirao K
Am J Cardiovasc Drugs; 2019 Dec; 19(6):597-605. PubMed ID: 31218508
[TBL] [Abstract][Full Text] [Related]
32. ACEI/ARB Medication During ICU Stay Decrease All-Cause In-hospital Mortality in Critically Ill Patients With Hypertension: A Retrospective Cohort Study Based on Machine Learning.
Yang B; Xu S; Wang D; Chen Y; Zhou Z; Shen C
Front Cardiovasc Med; 2021; 8():787740. PubMed ID: 35097006
[No Abstract] [Full Text] [Related]
33. Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study.
Lin SY; Ju SW; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Hsu CY; Kao CH
Clin Infect Dis; 2020 Dec; 71(10):2695-2701. PubMed ID: 32504531
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes.
Lo KB; Toroghi HM; Salacup G; Jiang J; Bhargav R; Quintero E; Balestrini K; Shahzad A; Mathew RO; McCullough PA; Rangaswami J
Rev Cardiovasc Med; 2021 Mar; 22(1):199-206. PubMed ID: 33792263
[TBL] [Abstract][Full Text] [Related]
36. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery.
Coca SG; Garg AX; Swaminathan M; Garwood S; Hong K; Thiessen-Philbrook H; Passik C; Koyner JL; Parikh CR;
Nephrol Dial Transplant; 2013 Nov; 28(11):2787-99. PubMed ID: 24081864
[TBL] [Abstract][Full Text] [Related]
37. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
[TBL] [Abstract][Full Text] [Related]
38. Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease.
Lapébie FX; Bura-Rivière A; Lacroix P; Constans J; Boulon C; Messas E; Aboyans V; Ferrières J; Bongard V
Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):463-474. PubMed ID: 32271868
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease.
Bhandari S; Mehta S; Khawaja A; Cleland JGF; Ives N; Cockwell P
Kidney Int; 2024 Jan; 105(1):200-208. PubMed ID: 37783444
[TBL] [Abstract][Full Text] [Related]
40. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
